Poolbeg Pharma announced the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team.
These experienced professionals will assume pivotal roles within Poolbeg, further enhancing the Company’s expertise and capabilities. Poolbeg’s Chairman, Cathal Friel, co-founded both Poolbeg and Amryt Pharma plc. Poolbeg intends to follow a similar strategic approach to Amryt which focusses upon developing a number of exciting clinical assets and the acquisition of approved and marketed drugs, which not only generate revenue but also fund the development of a robust pipeline of innovative products.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
